Is it time for me to buy this rallying FTSE 100 stock? Bank of America thinks so!

Major brokers are getting excited about this troubled FTSE 100 stock. I decided to find out what the fuss is all about — and I wasn’t disappointed.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Earlier this week, Bank of America put in a Buy rating on the FTSE 100 medical firm Smith & Nephew (LSE: SN.). The vote of confidence was further established by an Outperform rating put in the following day by fellow broker Bernstein.

So what’s prompted this renewed faith in the medical technology company — and should I consider buying the shares now?

Troubled times

I’ve considered Smith & Nephew shares several times over the past year. However, lingering issues at the company have stopped me just short of buying. The shares are down 40% over the past five years, hitting a low of £8.96 last October. 

It’s a disappointing outlook for a stock that gained almost 300% in the decade prior to 2020.

During these troubled times, the firm’s gone through no less than three CEOs, due in part to salary disagreements. Most recently, the board narrowly approved a 30% pay rise for CEO Deepak Nath — but not without a significant pushback from shareholders.

In 2019, chief executive Namal Nawana reportedly stood down because his requests for higher pay couldn’t be met under UK corporate governance standards.

An active boost

With pandemic-era supply chain issues now all but resolved, I’d imagine things should start improving. Hospital surgeries are back in full operation and the materials needed for prosthetics are available for delivery. Moreover, the company recently received a much-needed boost from activist investor firm Cevian.

Last month, it acquired a 5.11% stake in Smith & Nephew with the aim to help get things back on track. It’s previously helped several other struggling company’s to recover, with its members currently serving on 10 boards globally. Since Cevian made its acquisition less than two months ago, the share price has jumped a huge 20%. 

Oh no, am I late to the party? I don’t think so. With much room still to grow, I’m wondering if the price could regain the all-time high of nearly £20 it achieved in 2019.

What do the financials say?

Smith & Nephew’s valuation looks fairly attractive. The shares are estimated to be undervalued by 33% using a discounted cash flow model. It also has a forward price-to-earnings (P/E) ratio of 22.8, well below the industry average of 30. That’s a big improvement on its trailing P/E of 44, as earnings are expected to grow 80% in the coming 12 months.

In its first-half 2024 results, earnings per share (EPS) increased 20% to 24p, with revenue and income up 3.4% and 24% respectively. Unfortunately, with only a 2.4% yield, the company doesn’t offer much in the way of dividends. However, payments were growing prior to 2019 so that might continue if things go well.

Its joint US business continues to lose some ground to competitors but, elsewhere, the Hip and Knee Implants division is up, along with Sports Medicine and ENT. 

While progress has been good, the threat of supply chain disruptions remains a significant risk. Ensuring operations continue uninterrupted while growing the US business will likely be a key concern for the company going forward.

However, I’m very enthusiastic about the direction it’s headed and have firmly put the shares on my to-buy list for next month.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bank of America is an advertising partner of The Ascent, a Motley Fool company. Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

How I’m trying to make a million from passive income

Invest as much as possible, regularly, and use the passive income to plough back into more shares. Here's how millionaires…

Read more »

Investing Articles

I’d buy 30,434 shares of this UK dividend stock to target £175 a month in passive income

A top insider has spent over £1m buying this 9%-yielding passive income share over the last year. Roland Head explains…

Read more »

Growth Shares

Should I buy Rolls-Royce shares for 2025?

Edward Sheldon’s missed out on the huge gains that Rolls-Royce shares have generated this year. But should he buy the…

Read more »

Investing Articles

30,000 shares in this FTSE 250 REIT could earn me £559 a month in passive income

Real estate investment trusts can be great passive income investments. And Stephen Wright likes one from the FTSE 250 with…

Read more »

Investing Articles

Down 24% and yielding 9.18! Is L&G the best passive income stock on the FTSE?

Harvey Jones is the first to admit that the Legal & General share price has had a poor year. But…

Read more »

Investing Articles

Warren Buffett just bought these 2 stocks!

Warren Buffett just invested $700m in these stocks! What’s the strategy behind them, and should investors think about following in…

Read more »